Screening the Receptorome Yields Validated Molecular Targets for Drug Discovery

Author(s): Wesley K. Kroeze, Bryan L. Roth

Journal Name: Current Pharmaceutical Design

Volume 12 , Issue 14 , 2006

Become EABM
Become Reviewer
Call for Editor


With the recently completed sequencing and annotation of the human genome, it has become clear that a significant portion of the genome encodes signal-transducing molecules including receptors, protein kinases, ion channels, transporters and coupling proteins. This review focuses on membrane-localized receptors, which represent the largest single group of signal-transducing molecules. Indeed, one can estimate that nearly 10% of the human genome encodes membrane- localized receptors (e.g. G-protein coupled receptors, ligand-gated ion channels and transporters). We have defined that portion of the human genome that encodes receptors the receptorome. In this article, we will demonstrate how the massively parallel screening of the receptorome provides a facile and under-utilized screening platform for drug discovery. Using case studies, we will show how receptorome-based screening elucidates the mechanisms responsible for serious side-effects of both approved and investigational medications. Additionally, we will provide evidence that receptorome- based screening provides insights into novel therapeutic indications of approved medications and serves to validate targets for therapeutic drug discovery.

Keywords: Obesity-Related Molecular Targets, In Silico Receptoromics, Receptor Databases, GPCR, NC-IUPHAR, Weight Gain

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [1785 - 1795]
Pages: 11
DOI: 10.2174/138161206776873680
Price: $65

Article Metrics

PDF: 6